Atlas Venture Life Science Advisors, LLC Q1 2024 Filing

Filed May 6, 2024

Portfolio Value

$1.1T

Holdings

16

Report Date

Q1 2024

Filing Type

13F-HR

All Holdings (16 positions)

#	Stock	Shares	Value	% Portfolio	Type
1	DYNDyne Therapeutics, Inc.	8,020,136	$227.7B	21.01%
2	KYMRKymera Therapeutics, Inc.	5,377,362	$216.2B	19.95%
3	IRONDisc Medicine, Inc.	2,287,233	$142.4B	13.14%
4	DAWNDay One Biopharmaceuticals, Inc.	6,430,257	$106.2B	9.80%
5	THRDThird Harmonic Bio, Inc.	10,907,859	$103.0B	9.50%
6	KRROKorro Bio, Inc.	1,119,292	$100.7B	9.30%
7	AVTEAerovate Therapeutics, Inc.	2,039,249	$60.3B	5.57%
8	QTTBQ32 Bio, Inc.	2,092,106	$35.6B	3.29%
9	GBIOGBXGeneration Bio, Co.	8,279,484	$33.7B	3.11%
10	VIGLVigil Neuroscience, Inc.	5,836,874	$19.9B	1.84%
11	REPLReplimune Group, Inc.	2,098,300	$17.1B	1.58%
12	—Ikena Oncology, Inc.	5,018,178	$7.1B	0.66%
13	—AvroBio, Inc.	4,541,381	$5.8B	0.54%
14	DNTHDianthus Therapeutics, Inc.	186,979	$5.6B	0.52%
15	XLOXilio Therapeutics, Inc.	992,912	$1.1B	0.10%
16	SPROSpero Therapeutics, Inc.	607,613	$1.0B	0.10%